Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.84 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.84 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.84 |
| ▸ | DRD4 | P21917 | 4/20 | 0.65 |
| ▸ | DRD2 | P14416 | 5/20 | 0.65 |
| ▸ | DRD3 | P35462 | 5/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.65 |
| ▸ | HRH1 | P35367 | 4/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.65 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.65 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.65 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.65 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.65 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10733564 | 0.95 | OPRM1 (0.84) | OPRM1OPRL1OPRK1OPRD1DRD4 | |
| SCHEMBL7847623 | 0.91 | OPRL1 (1.00) | OPRM1OPRL1OPRK1OPRD1DRD4 | |
| SCHEMBL3895657 | 0.89 | OPRM1 (0.67) | OPRM1OPRL1OPRK1OPRD1DRD4 | |
| SCHEMBL21634300 | 0.89 | OPRL1 (0.86) | OPRM1OPRL1OPRK1OPRD1DRD4 | |
| SCHEMBL8894175 | 0.88 | OPRL1 (0.84) | OPRM1OPRL1OPRK1OPRD1DRD4 | |
| SCHEMBL16876793 | 0.88 | OPRL1 (0.84) | OPRM1OPRL1OPRK1OPRD1DRD4 | |
| SCHEMBL16876775 | 0.88 | OPRL1 (0.84) | OPRM1OPRL1OPRK1OPRD1DRD4 | |
| SCHEMBL20187104 | 0.87 | OPRL1 (0.78) | OPRM1OPRL1OPRK1OPRD1DRD4 | |
| SCHEMBL20187118 | 0.86 | OPRM1 (0.73) | OPRM1OPRL1OPRK1OPRD1DRD4 | |
| SCHEMBL21634308 | 0.85 | OPRL1 (0.78) | OPRM1OPRL1OPRK1OPRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829579-B1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S P A (IT) | 2023-08-02 | — | — | EP | claimed |
| EP-3829579-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | Maria Cecilia Hospital S.p.A. (IT) | 2021-06-09 | — | — | EP | claimed |
| WO-2020021378-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S.P.A. (IT) | 2020-01-30 | — | — | WO | claimed |
| EP-3829579-B1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S P A (IT) | 2023-08-02 | — | — | EP | disclosed |
| EP-3829579-B1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S P A (IT) | 2023-08-02 | — | — | EP | disclosed |
| EP-3829579-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | Maria Cecilia Hospital S.p.A. (IT) | 2021-06-09 | — | — | EP | disclosed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020021378-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S.P.A. (IT) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020021378-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S.P.A. (IT) | 2020-01-30 | — | — | WO | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | OPRM1 4280/4885OPRL1 2399/4885OPRK1 3749/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | OPRM1 4280/4885OPRL1 2399/4885OPRK1 3749/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | OPRM1 4280/4885OPRL1 2399/4885OPRK1 3749/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | OPRM1 4280/4885OPRL1 2399/4885OPRK1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.